Immunotherapy and chemo before and after pancreatic tumor surgery
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This Phase 2 trial tests a combination of immunotherapy (sintilimab) and chemotherapy (nab-paclitaxel and gemcitabine) given before surgery and again after surgery for pancreatic cancer that can be removed (or close to removable). It aims to improve outcomes by shrinking the tumor before the operation and reducing the chance of return after surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old
- Your cancer diagnosis is confirmed as pancreatic adenocarcinoma by tissue testing (biopsy)
- Your scan shows your pancreatic tumor is resectable or borderline resectable, and tumor imaging is done for this trial
- You have not had any cancer treatment for your pancreatic cancer yet (no chemo, radiation, immunotherapy, targeted drugs, or similar treatments)
- Your overall health is fairly strong (ECOG 0–1), and blood counts and organ tests are within allowed ranges
- You can attend study visits and follow the treatment plan
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of four drugs (liposomal irinotecan, 5-fluorouracil, oxaliplatin, and adebrelimab) given with radiation therapy before surgery for pancreatic cancer that can be surgically removed or is borderline removable. The goal is to shrink the tumor and improve the chances of successful surgery.
This trial tests if giving a combination of four drugs before and after surgery can help treat pancreatic cancer. The drugs include HRS-4642, gemcitabine, nab-paclitaxel, and adebrelimab. It may help shrink the tumor before surgery and lower the chance of cancer coming back afterward.
This trial tests a combination of an immunotherapy drug (adebrelimab) with two chemotherapy drugs (gemcitabine and nab-paclitaxel) for people with advanced pancreatic cancer that has progressed after prior treatment. The goal is to see if adding immunotherapy can help shrink tumors or slow the cancer down.
This trial tests adding the immunotherapy drug adebrelimab to standard chemotherapy before surgery for pancreatic cancer that can be removed. The goal is to see if this combination shrinks tumors more effectively.
This trial compares two approaches for patients with pancreatic or periampullary cancer that can be surgically removed: getting chemotherapy before surgery (neoadjuvant therapy) versus surgery first. It aims to find out which sequence leads to better outcomes.
This Phase 2 trial tests a chemotherapy plan given before surgery (called “neoadjuvant” treatment) for people with pancreatic adenocarcinoma that looks resectable or borderline resectable on scans. The goal is to see how well this adaptive chemotherapy approach works and whether it can improve outcomes before an operation.
Hear when a new Pancreatic Cancer Stage III trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.